The Headache Institute

Clinical Trials

  • Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Hoffmann-La Roche
    More Information
    More Information: Click here to learn more.
  • A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
    Recruitment Status
    Active: Not Recruiting
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Eisai Inc.
    More Information
    More Information: Click here to learn more.
  • Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Eli Lilly and Company
    More Information
    More Information: Click here to learn more.
  • A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
    Recruitment Status
    Active: Not Enrolling
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Eisai Inc.
    More Information
    More Information: Click here to learn more.
  • Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: TauRx Therapeutics Ltd
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Avanir Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease
    Recruitment Status
    Active: Enrollment Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Hoffmann-La Roche
    More Information
    More Information: Click here to learn more.
  • Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2)
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Prilenia
    More Information
    More Information: Click here to learn more.
  • HEALEY ALS Platform Trial
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: NEALS
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Cytokinetics
    More Information
    More Information: Click here to learn more.
  • PLS Natural History (PNHS) Study
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: 
    Sponsor
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    More Information
    More Information: Click here to learn more.
  • TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Individual Patient Use
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: TauRx Therapeutics Ltd
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Pfizer
    More Information
    More Information: Click here to learn more.
  • A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Pfizer
    More Information
    More Information: Click here to learn more.
  • A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC
    More Information
    More Information: Click here to learn more.
  • A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Pfizer
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Pfizer
    More Information
    More Information: Click here to learn more.
  • A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Baxalta now part of Shire
    More Information
    More Information: Click here to learn more.
  • A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease
    Recruitment Status
    Completed: 2016
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Merck Sharp & Dohme Corp.
    More Information
    More Information: Click here to learn more.
  • A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Merck Sharp & Dohme Corp.
    More Information
    More Information: Click here to learn more.
  • Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Eli Lilly and Company
    More Information
    More Information: Click here to learn more.
  • A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Cerecin
    More Information
    More Information: Click here to learn more.
  • A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: AstraZeneca
    More Information
    More Information: Click here to learn more.
  • A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Merck Sharp & Dohme Corp.
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Avanir Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Hoffmann-La Roche
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
    Recruitment Status
    Closed
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: Avanir Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning Study: A Study to Improve Precision in Amyloid PET Coverage and Patient Care
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: Alzheimer's Disease (AD)
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Amylyx Pharmaceuticals Inc.
    More Information
    More Information: Click here to learn more.
  • Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
    Recruitment Status
    Closed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Amylyx Pharmaceuticals Inc.
    More Information
    More Information: Click here to learn more.
  • Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
    Recruitment Status
    Closed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Orion Corporation, Orion Pharma
    More Information
    More Information: Click here to learn more.
  • Analysis of Transcriptional Changes in Blood Samples from Patients with Neurologic Diseases
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Neurologix Foundation
    More Information
    More Information: Click here to learn more.
  • Safety Study of Oral Edaravone Administered in Subjects With ALS
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.
    More Information
    More Information: Click here to learn more.
  • Speech Movement Patterns of Individuals with Amyotrophic Lateral Sclerosis
    Recruitment Status
    Closed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: An NIH-funded project that is being conducted at the University of Texas at Dallas in collaboration with Texas Neurology. The goal of this study is to advance the diagnosis, assessment, and treatment of speech motor impairment due to ALS using novel, computational approaches.
    More Information
    More Information: Click here to learn more.
  • Centers for Disease Control IRB - Protocol 5923.0 – “Proposal for the State and Metropolitan Area-Based ALS Surveillance”
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • Texas Department of State Health Services IRB – # 10-036 – “Texas Amyotrophic Lateral (ALS) Surveillance Activity”
    Recruitment Status
    Completed
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • ALS Patient Care Database
    Recruitment Status
    Completed: 2007
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)
    Recruitment Status
    Completed: 2009
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Avanir Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed: 2009
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Massachusetts General Hospital
    More Information
    More Information: Click here to learn more.
  • TIV(Tracheostomy with invasive ventilation) for Patients with ALS in Japan and the USA: A Comparitive Study
    Recruitment Status
    Completed: 2011
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Columbia University and the MDA
    More Information
    More Information: Click here to learn more.
  • Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Massachusetts General Hospital
    More Information
    More Information: Click here to learn more.
  • A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Knopp Biosciences
    More Information
    More Information: Click here to learn more.
  • Collection of Blood Samples for DNA Analysis in Motor Neuron Diseases
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
    More Information
    More Information: Click here to learn more.
  • An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Knopp Biosciences
    More Information
    More Information: Click here to learn more.
  • Analysis of Transcriptional Changes in Blood Samples from Patients with Neurologic Disease
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Baylor Research Institute
    More Information
    More Information: Click here to learn more.
  • Northeast ALS (NEALS) Consortium: The Upper Motor Neuron Disease (UMND) Pilot Registry
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
    Recruitment Status
    Completed: 2014
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Cytokinetics
    More Information
    More Information: Click here to learn more.
  • A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis
    Recruitment Status
    Completed: 2014
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Mallinckrodt
    More Information
    More Information: Click here to learn more.
  • Biogen Idec Evidera ALS Study: Qualitative Investigation of Signs and Related Functional Decline in Patients with Amyotrophic Lateral Sclerosis(ALS)
    Recruitment Status
    Completed: 2015
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Biogen Idec, Inc.
    More Information
    More Information: Click here to learn more.
  • ALS COSMOS (ALS Cohort Study of Multicenter Oxidative Stress)
    Recruitment Status
    Completed: 2016
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: National Institute of Health (NIH)
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Cytokinetics
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Cytokinetics
    More Information
    More Information: Click here to learn more.
  • A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment.
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Aquestive Therapeutics
    More Information
    More Information: Click here to learn more.
  • Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Biohaven Pharmaceuticals, Inc.
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Mallinckrodt
    More Information
    More Information: Click here to learn more.
  • A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Cytokinetics
    More Information
    More Information: Click here to learn more.
  • Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS
    Recruitment Status
    Completed: 2020
    Condition
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    Sponsor
    Sponsor: Johns Hopkins University
    More Information
    More Information: Click here to learn more.
  • A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults with ALS
    Recruitment Status
    Closed
    Condition
    Condition: 
    Sponsor
    Condition: Amyotrophic Lateral Sclerosis (ALS)
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
    Recruitment Status
    Closed
    Condition
    Condition: Cervical Dystonia/Spasmodic Torticollis
    Sponsor
    Sponsor: Revance Therapeutics, Inc.
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
    Recruitment Status
    Closed
    Condition
    Condition: Cervical Dystonia/Spasmodic Torticollis
    Sponsor
    Sponsor: Revance Therapeutics, Inc.
    More Information
    More Information: Click here to learn more.
  • Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial
    Recruitment Status
    Closed
    Condition
    Condition: Epilepsy (Epilepsy)
    Sponsor
    Sponsor: Bial - Portela C S.A.
    More Information
    More Information: Click here to learn more.
  • PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
    Recruitment Status
    Closed
    Condition
    Condition: Epilepsy (Epilepsy)
    Sponsor
    Sponsor: Pfizer
    More Information
    More Information: Click here to learn more.
  • Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
    Recruitment Status
    Completed: 2013
    Condition
    Condition: Epilepsy (Epilepsy)
    Sponsor
    Sponsor: Sunovion
    More Information
    More Information: Click here to learn more.
  • An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Epilepsy (Epilepsy)
    Sponsor
    Sponsor: UCB Pharma
    More Information
    More Information: Click here to learn more.
  • Long Term Eslicarbazepine Acetate Extension Study
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Epilepsy (Epilepsy)
    Sponsor
    Sponsor: Sunovion
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension
    Recruitment Status
    Closed
    Condition
    Condition: Migraine (headache)
    Sponsor
    Sponsor: Impax Laboratories, LLC
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Allergan
    More Information
    More Information: Click here to learn more.
  • A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Activecontrolled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
    Recruitment Status
    Active: Recruiting
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache
    Recruitment Status
    Closed
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: 
    More Information
    More Information: Click here to learn more.
  • NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial
    Recruitment Status
    Completed: 2010
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Anne Lindblad
    More Information
    More Information: Click here to learn more.
  • An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
    Recruitment Status
    Completed: 2010
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: NuPathe Inc.
    More Information
    More Information: Click here to learn more.
  • Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial
    Recruitment Status
    Completed: 2012
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Abbott Medical Devices
    More Information
    More Information: Click here to learn more.
  • A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention
    Recruitment Status
    Completed: 2016
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults With Chronic Migraine
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Allergan
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Allergan
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Allergan
    More Information
    More Information: Click here to learn more.
  • A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
    Recruitment Status
    Completed: 2018
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Alder Biopharmaceuticals, Inc.
    More Information
    More Information: Click here to learn more.
  • A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
    Recruitment Status
    Completed: 2019
    Condition
    Condition: Migraine
    Sponsor
    Sponsor: Amgen
    More Information
    More Information: Click here to learn more.
  • Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
    Recruitment Status
    Closed
    Condition
    Condition: MS
    Sponsor
    Sponsor: Novartis Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis
    Recruitment Status
    Closed
    Condition
    Condition: MS
    Sponsor
    Sponsor: Mallinckrodt
    More Information
    More Information: Click here to learn more.
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
    Recruitment Status
    Completed: 2005
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
    Recruitment Status
    Completed: 2006
    Condition
    Condition: MS
    Sponsor
    Sponsor: PDL BioPharma, Inc.
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
    Recruitment Status
    Completed: 2009
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis
    Recruitment Status
    Completed: 2011
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
    Recruitment Status
    Completed: 2012
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)
    Recruitment Status
    Completed: 2012
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis
    Recruitment Status
    Completed: 2012
    Condition
    Condition: MS
    Sponsor
    Sponsor: Acorda Therapeutics
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)
    Recruitment Status
    Completed: 2015
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)
    Recruitment Status
    Completed: 2016
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
    Recruitment Status
    Completed: 2016
    Condition
    Condition: MS
    Sponsor
    Sponsor: Adamas Pharmaceuticals, Inc.
    More Information
    More Information: Click here to learn more.
  • A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules
    Recruitment Status
    Completed: 2017
    Condition
    Condition: MS
    Sponsor
    Sponsor: Biogen
    More Information
    More Information: Click here to learn more.
  • A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
    Recruitment Status
    Completed: 2018
    Condition
    Condition: MS
    Sponsor
    Sponsor: Novartis Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis
    Recruitment Status
    Active: Enrollment Closed
    Condition
    Condition: Myasthenia Gravis
    Sponsor
    Sponsor: Alexion Pharmaceuticals
    More Information
    More Information: Click here to learn more.
  • Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Neuropathy
    Sponsor
    Sponsor: University of Kansas Medical Center
    More Information
    More Information: Click here to learn more.
  • Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
    Recruitment Status
    Closed
    Condition
    Condition: Parkinson's Disease (PD)
    Sponsor
    Sponsor: Eli Lilly and Company
    More Information
    More Information: Click here to learn more.
  • This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.
    Recruitment Status
    Completed: 2016
    Condition
    Condition: Stroke
    Sponsor
    Sponsor: Acorda Therapeutics
    More Information
    More Information: Click here to learn more.
  • An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .
    Recruitment Status
    Completed: 2017
    Condition
    Condition: Stroke
    Sponsor
    Sponsor: Acorda Therapeutics
    More Information
    More Information: Click here to learn more.
  • A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
    Recruitment Status
    Completed: 2014
    Condition
    Condition: Other (HIV)
    Sponsor
    Sponsor: Gilead Sciences
    More Information
    More Information: Click here to learn more.
  • A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
    Recruitment Status
    Active: Not Recruiting
    Condition
    Condition: Other (Inclusion body myositis (IBM))
    Sponsor
    Sponsor: Abcuro, Inc. (Responsible Party)
    More Information
    More Information: Click here to learn more.